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Introduction: Varicose vein surgery for recurrent disease can result from inadequate primary surgery.
Redo open surgery is more difﬁcult to perform than primary surgery and can be associated with a higher
incidence of neurovascular injury and infection. In this study we evaluate EVLA, a percutaneous tech-
nique that uses intra-operative duplex ultrasound as an option for the treatment of recurrent varicose
veins.
Materials and Methods: Data prospectively collected on patients who had EVLA for varicose veins were
obtained from our dedicated vascular registry. From November 2004 to December 2008 we performed
586 EVLA procedures, 77 procedures were for recurrent varicose veins.
Results: The mean age was 52  12.77 years, range 28e80; and 48 (62%) were female. 64 (83%) cases
were for recurrent LSV disease, 13 (17%) cases for recurrent SSV disease and all patients had LSV or SSV
incompetence conﬁrmed on preoperative duplex assessment. Median duration since primary surgery
was 60 months (range 2e360). Mean length of vein treated was LSV e 36 cm  14.5 (6e73) and SSV e
14.5 cm  7.35 (5e24); mean energy delivered was LSV 3102J  1053 (150e4656) and SSV e 693J  396
(135e1216). 17 patients had bilateral EVLA for recurrent disease at the same setting with one patient
having bilateral procedures under local anaesthetic. There was an incidence of pulmonary embolism 10
days post EVLA and two patients required further phlebectomies post EVLA for residual varices that were
present pre-operatively. Median follow-up was 18 months (range 1e38), with no clinical recurrence and
no recannalisation of the treated LSV or SSV on duplex ultrasound.
Conclusions: In our experience EVLA can be safely performed for recurrent varicose vein disease. In our
experience Redo EVLA is not more difﬁcult than primary EVLA to perform.
 2010 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Ligation and stripping of varicose veins has a recurrence rate of
up to 40% at 5 years and 20% of all varicose vein operations are for
recurrence.1 Surgery for recurrent disease (redo surgery) is poten-
tially hazardous because scar tissue distorts the normal architecture
making identiﬁcation of the target anatomy difﬁcult. As a result
there is potentially a greater risk of iatrogenic injury to neigh-
bouring structures during dissection in redo surgery compared to
primary surgery. The more extensive and difﬁcult dissections
sometimes required in redo surgery, and hence longer operatingr and Endovascular Surgery,
ospital, Whitechapel, London
073777684.
tsandthelondon.nhs.uk (C.
ciates Ltd. Published by Elsevier Lttimes, mean longer exposure to general anaesthetic for patients
compared to primary surgery. Haemostasis is more difﬁcult in redo
surgery and hence a higher risk of haematoma formation; this with
longer operating times and the disruption of normal tissue blood
ﬂow in scar tissue make wound infections more common following
redo surgery compared to primary surgery.
During the past decade, increased interest in venous disorders
and the development of minimally invasive treatment options such
as Endovenous Laser Ablation (EVLA), has led to advancement in
the management of varicose veins. EVLA allows delivery of laser
energy directly into the blood vessel lumen to produce irreversible
occlusion with subsequent ﬁbrosis. The resultant functional oblit-
eration of the saphenous vein is less invasive than open surgery,
avoids major dissection and can be performed under local anaes-
thetic as a day case, requiring no hospital stay.2,3
We evaluate the use of EVLA as an alternative to redo open
surgery for the treatment of recurrent varicose vein disease.d. All rights reserved.
Table 2
Distribution of cases.
Recurrent LSV Recurrent SSV
Total no of cases 64 (83%) 13 (17%)
Mean length of vein
treated (cm)
36  14.5
(range 6e73)
14.5  7.35
(range 5e24)
Mean energy delivered (J) 3102  1053
(range 150e4656)
693  396
(range 135e1216)
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Data prospectively collected on patients who had EVLA for
varicose veins were obtained from our dedicated vascular registry
and showed that from November 2004 to December 2008 we
performed 586 EVLA procedures of which 77 (13%) were for
recurrent varicose veins. 67 patients had previous ligation 
stripping  multiple phlebectomies; 6 patients had previous
multiple phlebectomies only; 4 patients had previous sclerotherapy
and the median duration since primary surgery at time of EVLAwas
60 months (range 2e360).
Informed consent had been obtained for EVLA in accordance
with The National Institute for Health and Clinical Excellence
(NICE) recommendations.4 Procedures were performed either
under local (LA) or general anaesthesia (GA), depending on patient
and surgeon preference, with strict aseptic technique. The proce-
dure is the same for primary and redo surgery with no modiﬁca-
tions and is as described in previous publications.5,6
With the patients adequately positioned the venous anatomy is
mapped with duplex ultrasound and marked with an indelible pen.
A 600-nm laser ﬁber (Diomed) is then positioned under ultrasound
guidance with the tip positioned 2 cm distal to the SFJ or SPJ to
avoid propagation of clot into the deep veins. Tumescent local
anaesthetic (100e200 mls of 0.2% Lignocaine) with adrenaline is
injected around the vein under ultrasound guidance. After appro-
priate laser safety precautions, laser energy is delivered at 100 J/cm
to the LSV and 50 J/cm to the SSV as the laser ﬁber with its sheath is
slowly withdrawn from the leg. Treatment is stopped about 1cm
above the needle entry point, the laser is switched off, laser and
catheter are removed then the puncture site controlled with
a compressive dressing to achieve haemostasis. Multiple phlebec-
tomies are then performed as required through micro-stab inci-
sions to sites marked pre-operatively with the patient standing.
These incisions are then controlled with pressure dressings.
Class 2 graduated compression stockings are required for
2 weeks (at all times for the ﬁrst week, then daytime only for the
second week). Oral analgesia is prescribed for at least 5 days,
a combination of Paracetamol and Diclofenac sodium is preferred if
there are no contraindications.3. Results
Median post operative follow-up was 18 months (range 1e38).
Patients had EVLA for recurrent disease with multiple phlebec-
tomies for varicosities as one procedure. Clinical classiﬁcation
(CEAP)7,8 on presentation was between C2 and C5 (Table 1). The
mean age of the patients at treatment for recurrent disease was
52  12.77 years, range 28e80; 48 (62%) were female; and median
body mass index was 25 (range 22e28). 64 (83%) cases were for
recurrent LSV disease, 13 (17%) cases for recurrent SSV disease and
all patients had LSV or SSV incompetence conﬁrmed on preopera-
tive duplex assessment. 69 (90%) cases were done under a general
anaesthetic. 17 patients had bilateral EVLA for recurrent disease at
the same settingwith one patient having bilateral procedures under
local anaesthetic. The distribution of cases is shown in Table 2.Table 1
Pre-operative clinical classiﬁcation (CEAP).
(Superﬁcial/reticular veins only) C1 0 limbs
(Simple varicose veins only) C2 32 limbs
(Ankle oedema of venous origin) C3 20 limbs
(Skin pigmentation in the gaiter area) C4 19 limbs
(Healed venous ulcer) C5 6 limbs
(Active venous ulcer) C6 0 limbsThere were no intra-operative complications and immediate
post-procedure duplex ultrasound conﬁrmed echogenic thrombus
formation in all target veins with no deep vein thrombus. All
patients were discharged from hospital the same day. One patient
presented to the emergency room 10 days following bilateral EVLA
for bilateral LSV disease with a pulmonary embolism.9 At 6-week
review two patients were found to have residual varices, present
pre-operatively, which were subsequently treated by phlebec-
tomies. At the 6-week review, there was no clinical evidence
of recurrence and no incidence of nerve injury either in terms of
sensory deﬁcit or paraesthesia. Over a median follow-up of
18 months (range 1e38), there was no clinical recurrence and no
recannalisation of the treated LSV or SSV on duplex ultrasound.4. Discussion
Following primary open surgery, reasons for recurrence include
inadequate initial operations where the site of valvular incompe-
tence is not treated as the anatomy can be quite variable e.g. in
a duplicate system where the wrong vein is ligated and stripped.
Failure to appreciate that there may be more than one site of
incompetence pre-operatively can also lead to early failure of the
operation if all sites of incompetence are not dealt with.10
A contentious issue is neo-vascularisation where re-growth of
tiny vein branches develop through scar tissue providing a new
connection between deep and superﬁcial vein even after initial
‘adequate’ primary surgery.11,12
Traditional redo open surgical treatment of recurrent varicose
vein disease is the ligation and division of the saphenous trunk
which is sometimes followed by stripping and avulsion phlebec-
tomy of tributaries. Scar tissue from the previous surgery can
complicate this procedure by distorting the normal anatomy
making dissection more difﬁcult. With redo open surgery there is
an increased incidence of surgical complications (paresthesia,
bleeding, infection and scarring), increased in-hospital costs and
prolonged recovery periods.10
EVLA was approved by the National Institute for Health and
Clinical Excellence (NICE) inMarch 2004. First described by Navarro
et al. (2001) for the treatment of incompetent long saphenous vein
segments,13 EVLA avoids the complications of open surgery with
better outcomes. The use of on-table ultrasound makes EVLA more
precise and there is less risk of inadequate surgery as the whole
length of varicose vein can be visualized during the procedure. The
EVLA procedure has been associated with minimal scarring
(as there is no groin incision), less bruising, faster recovery and
return to normal activity as well as lower recurrence rates.14 EVLA
can be accompanied by injection sclerotherapy or multiple avul-
sions for the removal of residual varicosities.
Our practice includes multiple phlebectomies via stab incisions
for all visible varicosities after EVLA therapy during the same
session.5,6 These varicosities are marked pre-operatively with the
patient in the standing position and with input from the patient.
This way the patient is less likely to present at a follow-up clinic
complaining that offending varices are still present post-
operatively.
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old lady patient who had underwent bilateral EVLA for recurrent
LSV disease 10 days earlier.9 BTS guidelines15 list potential risk
factors for PE, and in this patient they included advanced age,
previous bilateral ligation and stripping of the proximal great
saphenous vein a year earlier, malignancy and phlebitic tributary
varices. She had no clinical signs of a DVT on presentation with the
PE and subsequent duplex ultrasound showed no propagation of
thrombus from the treated LSVs to the deep veins. Because of this, it
is unclear if this lady’s PE was a direct consequence of the EVLA
procedure, but she was treated successfully and made a full
recovery.
Clinical success of EVLA is deﬁned as permanent occlusion of the
treated vein segments, abolition of reﬂux, successful elimination of
related varicose veins and improvement in the clinical classiﬁcation
of the limb by a certain time interval after the procedure.2,16 Min
et al. (2003) showed successful occlusion on follow-up Duplex
ultrasound in 490/499 (98%) limbs at 1 month, 390/396 (98.5%)
limbs at 6 months, 310/318 (97.5%) limbs at 1 year and 113/121
(93.4%) limbs at 2 years. 40 patients in the same study were fol-
lowed up to 3 years with no new recurrence; most recurrences
were found to occur by 3 months, with no new recurrences after
9 months.17
Over a median follow-up of 18 months (range 1e38), we found
no clinical evidence of recurrence and no recannalisation of the
treated LSV or SSV on duplex ultrasound.
Comparing EVLA to ligation and stripping; clinical success rates
of EVLA in larger series vary from 93 to 98%17,18 compared to
traditional ligation and stripping at 77e82%.19,20 There is also
a difference in recovery time; EVLA patients are encouraged to
resume normal activity immediatelywithmost returning to normal
activity and work with 1e2 days,17 but series have shown patients
after ligation and stripping on average return to normal activity at
3.9 days and return to work at 12.4 days.21
5. Conclusions
Our study shows EVLA as a viable alternative option in the
treatment of recurrent varicose veins. It avoids the perils of
dissecting through scar tissue from previous operations. EVLA is
also a safer and more precise treatment as the use of on-table
ultrasound guides the surgeon to the desired target anatomy with
less risk of incomplete surgery and undesirable iatrogenic injury to
the patient.
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